What guidance did Nano-x Imaging's management provide for the next earnings period?

What is Nano-x Imaging's latest dividend and current dividend yield?

What is the market's earnings forecast for Nano-x Imaging next quarter?

Did Nano-x Imaging beat or miss consensus estimates last quarter?

What is Nano-x Imaging's gross profit margin?

What were the key takeaways from Nano-x Imaging’s earnings call?

What is the revenue and EPS growth rate for Nano-x Imaging year over year?

What does Nano-x Imaging do and what are its main business segments?

- **Commercial Momentum**: 20+ systems scanning patients, 100+ leads for 2025 installations, and first EU shipment to Romania.
- **AI Expansion**: 12+ partnerships, 50+ Ezra Medical sites, and 2026 breakeven target for AI business.
- **Financial Update**: Q2 2025 GAAP loss of $14.7M, 38% non-GAAP teleradiology margin, and $62.6M cash balance.
- **Strategic Initiatives**: Mobile imaging solution in development, 2 NIH grants, and multiyear manufacturing contract with Fabrinet.

**【CEO Summary Section】**
- **Commercial Progress**: Targeting 100 Nanox.ARC system installations by year-end 2025, with 20+ systems actively scanning patients. Key U.S. partnerships include a major imaging chain (hundreds of locations) and Keiser University for training programs. EU expansion underway with first shipment to Romania and discussions in Greece.
- **AI Collaborations**: 12+ partnerships with leading AI platforms (e.g., Ezra Medical, deepcOS) to integrate Nanox.AI solutions. Notable collaborations include Duke University for clinical studies and CTIS for NIH grants on vaping-related gland cancer.
- **Clinical Development**: Published study in Biomedical Physics showing Nanox.ARC's superior motion artifact management. Added 2 key opinion leaders to Medical Advisory Board. Mobile imaging solution in development for rural access.
- **Manufacturing**: Signed multiyear contract with Fabrinet for scalable production of Nanox.ARC X. Transitioning to Varex glass tubes for cost efficiency, with first demonstrators expected in Q3.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: GAAP net loss of $14.7M (vs. $13.6M in Q2 2024). Revenue of $3.0M (+11% YoY) driven by teleradiology services ($2.7M, 18% GAAP gross margin). Non-GAAP net loss of $10.9M (+30% YoY) due to higher operating expenses.
- **Revenue Breakdown**: 
  - Teleradiology: $2.7M (+8% YoY), 38% non-GAAP gross margin
  - Imaging systems: $0.2M (+225% YoY), 85% gross loss
  - AI solutions: $0.1M, 99% gross loss
- **Expense Management**: Flat OpEx at $11.8M (vs. Q1 2025), with $1.2M sales/marketing investment for U.S. commercialization. Cash balance of $62.6M as of June 30, 2025.

**【Q&A Key Highlights】**
- **System Utilization**: 20+ systems actively scanning patients (vs. ~10 in Q1). 100+ leads identified for 2025 installations, with ~80% in U.S.
- **Revenue Model**: ~50% CapEx sales (EU, select U.S. accounts), 50% MSaaS. First CapEx deal in U.S. closed in Q2.
- **AI Growth**: 2026 target for AI breakeven. Ezra Medical installations growing to 50+ sites, with plans to double revenue contribution.
- **Geographic Focus**: U.S. (8 states approved), EU (Romania, Greece), Mexico (permits pending), and India (2 pilot projects). No immediate focus on Asia-Pacific or Africa.
- **Clinical Pipeline**: 2 NIH grants for vaping-related cancer studies. Mobile imaging solution expected to launch in 2026.


Nano-X Imaging Ltd. (NNOX) Q2 2025 Earnings Call Transcript

- **Commercial Expansion**: 1,000+ global leads and 60+ Nanox.ARC units in deployment, targeting 100+ by year-end 2025.
- **AI Growth**: Nanox.AI revenue up 100% YoY; 3 pilot programs with top academic centers.
- **Profitability Roadmap**: USARAD profitable; AI break-even in 2026; ARC breakeven in 2027 with 1,500-2,000 units.
- **Key Markets**: 70%+ 2025 units in US; 15-20% in Europe; 10% in emerging markets.
- **Revenue Drivers**: Workers' comp ($120-180/patient), AI ($75-100/scan), and Nanox.AI integration (20 scans/month).

**【CEO Opening Remarks】**
- **Strategic Acquisitions**: USARAD (teleradiology) and Nanox.AI (AI imaging) integrated into the Nanox.ARC ecosystem, driving end-to-end medical imaging solutions.
- **Commercial Progress**: 
  - 1,000+ sales pipeline leads across 20+ countries (e.g., Peru, France, Poland).
  - 60 Nanox.ARC units in deployment stages globally, targeting 100+ by year-end 2025.
  - Average 7 scans/day per operational unit, with potential for higher volumes in specialty clinics.
- **AI Solutions Momentum**: 
  - Trial data shows strong performance; 3 pilot programs with academic centers (e.g., Oxford, Duke).
  - Ezra AI partnership to expand AI adoption in 30+ US locations.
- **International Expansion**: 
  - CE mark for Nanox.ARC secured; demo units en route to Greece, Romania, Mexico.
  - Workers' compensation project in US with 120-180$/patient pricing.
- **Clinical & Regulatory Success**: 
  - FDA 510(k) clearance for Nanox.ARC X system.
  - Shamir Hospital trial underway; multi-site clinical trials expanding.

**【CFO Financial Highlights】**
- **Q1 2025 Results**: 
  - GAAP Net Loss: $13.2M (vs. $12.2M YoY).
  - Revenue: $2.8M (vs. $2.6M YoY), driven by USARAD (+17% GAAP gross margin).
  - Non-GAAP Gross Loss: $0.4M (vs. $0.6M YoY gross profit).
- **Business Line Performance**: 
  - **Teleradiology**: $2.6M revenue, 39% non-GAAP gross margin (up from 37% YoY).
  - **AI Solutions**: $0.2M revenue, transitioning to break-even in 2026.
  - **ARC Systems**: $33K revenue, targeting 2027 breakeven with 1,500-2,000 units deployed.
- **Balance Sheet**: $72.9M cash and equivalents as of March 31, 2025.

**【Q&A Key Takeaways】**
- **Deployment Timeline**: 
  - 70%+ of 2025 units in US; 15-20% in Europe; 10% in Latin America/Africa.
  - 20+ operational units in US, with 11-17 scans/day in specialty clinics.
- **Profitability Path**: 
  - USARAD already profitable; AI break-even in 2026; ARC breakeven in 2027.
  - Inflection point expected in 2H 2025 with regulatory approvals and EOB reimbursements.
- **Revenue Growth Drivers**: 
  - Workers' comp segment ($100M+ potential).
  - AI solutions pricing ($75-100+/scan).
  - Nanox.AI teleradiology integration (20 scans/month).

Nano-X Imaging Ltd. (NNOX) Q1 2025 Earnings Call Transcript

- **Regulatory Wins**: FDA general use clearance and EU CE Mark enable broader market access.
- **Commercial Momentum**: 20+ U.S. installations, 25% AI customer growth, and new EU partnerships.
- **Financial Snapshot**: Q4 2024 GAAP net loss of $14.1M, with $3.0M revenue driven by teleradiology.
- **Strategic Moves**: Nanox.ARC-X FDA submission, OEM partnerships to secure supply chains, and $37.8M ATM raise.

**【Management Opening Remarks】**
- Earnings call participants: CEO Erez Meltzer, CFO Ran Daniel, and IR head Mike Cavanaugh.
- Reminder of forward-looking statements and non-GAAP financial measures.

**【CEO Summary Section】**
- **Regulatory Milestones**: FDA general use clearance for Nanox.ARC in December 2024 and CE Mark for EU market entry in February 2025.
- **Commercial Progress**: 
  - U.S. deployment: 20+ systems in various stages of installation across 7 states, with 10 daily scans at a multi-specialty clinic.
  - New channel partners: ASI (Georgia) and agreements in Romania and Greece for EU expansion.
  - AI growth: 25% increase in AI customers, including partnerships with Blackford and Ezra for imaging analytics.
- **Product Pipeline**: Submission of Nanox.ARC-X for FDA clearance, featuring a 1-day setup and plug-and-play functionality.
- **OEM Partnerships**: Collaborations with Varex and a global medical solutions provider to secure tube supply chains.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: 
  - GAAP net loss: $14.1M (vs. $10.2M in Q4 2023), driven by one-time legal expenses.
  - Revenue: $3.0M (vs. $2.4M), with 87% from teleradiology services.
  - Gross loss: $2.9M (GAAP) / $0.3M (Non-GAAP), reflecting higher system deployment costs.
- **Balance Sheet**: $83.5M cash and marketable securities, with $3.1M bank loan.
- **Share Activity**: Issued 5M shares under ATM program, raising $37.8M net.

**【Q&A Highlights】**
- **Sales Models**: U.S. systems sold via CapEx and MSaaS; EU expected to favor CapEx sales.
- **Manufacturing**: Tubes sourced from Varex (Italy) and System (Switzerland), with chips produced in Korea.
- **2025 Outlook**: Focus on EU market penetration, AI expansion, and Nanox.ARC-X FDA approval.
- **Cash Position**: No guidance on cash runway or profitability, but CFO emphasized prudent capital allocation.


NNOX

NNOX fundamentals

Earnings Call

You can ask Aime